BUTYROLACTONE-I, A SELECTIVE INHIBITOR OF CDK2 AND CDC2 KINASE

被引:0
|
作者
KITAGAWA, M
OKABE, T
OGINO, H
MATSUMOTO, H
SUZUKITAKAHASHI, I
KOKUBO, T
HIGASHI, H
SAITOH, S
TAYA, Y
YASUDA, H
OHBA, Y
NISHIMURA, S
TANAKA, N
OKUYAMA, A
机构
[1] MERCK RES LABS, BANYU TSUKUBA RES INST COLLABORAT, OKUBO 3, TSUKUBA 30033, JAPAN
[2] NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN
[3] KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.
引用
收藏
页码:2425 / 2432
页数:8
相关论文
共 50 条
  • [21] Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity
    Booher, RN
    Holman, PS
    Fattaey, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) : 22300 - 22306
  • [22] COEXPRESSION OF CDK2/CDC2 AND RETINOBLASTOMA GENE-PRODUCTS IN COLORECTAL-CANCER
    YAMAMOTO, H
    MONDEN, T
    IKEDA, K
    IZAWA, H
    FUKUDA, K
    FUKUNAGA, M
    TOMITA, N
    SHIMANO, T
    SHIOZAKI, H
    MONDEN, M
    BRITISH JOURNAL OF CANCER, 1995, 71 (06) : 1231 - 1236
  • [23] Cdc2: a monopotent or pluripotent CDK?
    Hu, X.
    Moscinski, L. C.
    CELL PROLIFERATION, 2011, 44 (03) : 205 - 211
  • [24] Fas-induced changes in cdc2 and cdk2 kinase activity are not sufficient for triggering apoptosis in HUT-78 cells
    DeLuca, A
    DeMaria, R
    Baldi, A
    Trotta, R
    Facchiano, F
    Giordano, A
    Testi, R
    Condorelli, G
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1997, 64 (04) : 579 - 585
  • [25] CHARACTERIZATION OF THE IN-VITRO RECONSTITUTED CYCLIN-A OR B1-DEPENDENT CDK2 AND CDC2 KINASE-ACTIVITIES
    PAN, ZQ
    AMIN, A
    HURWITZ, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (27) : 20443 - 20451
  • [26] DISTINCT ROLES OF CDK2 AND CDC2 IN RP-A PHOSPHORYLATION DURING THE CELL-CYCLE
    FANG, F
    NEWPORT, JW
    JOURNAL OF CELL SCIENCE, 1993, 106 : 983 - 994
  • [27] ISOLATION AND CHARACTERIZATION OF GOLDFISH CDK2, A COGNATE VARIANT OF THE CELL-CYCLE REGULATOR CDC2
    HIRAI, T
    YAMASHITA, M
    YOSHIKUNI, M
    TOKUMOTO, T
    KAJIURA, H
    SAKAI, N
    NAGAHAMA, Y
    DEVELOPMENTAL BIOLOGY, 1992, 152 (01) : 113 - 120
  • [28] Inhibition of CDC2 and CDK2 and radiosensitization of human glioblastoma cells by the staurosporine derivative CGP 41251
    Begemann, M
    Kashimawo, A
    Heitjan, DF
    Schiff, PB
    Bruce, JN
    Weinstein, IB
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 2133 - 2133
  • [29] BOTH CDC2 AND CDK2 PROMOTE S-PHASE INITIATION IN XENOPUS EGG EXTRACTS
    CHEVALIER, S
    TASSAN, JP
    COX, R
    PHILIPPE, M
    FORD, C
    JOURNAL OF CELL SCIENCE, 1995, 108 : 1831 - 1841
  • [30] PHOSPHORYLATION OF MARCKS AND MAP2 BY CDC2 KINASE AND CDK5
    YAMAMOTO, H
    ARAKANE, F
    HISANAGA, S
    FUKUNAGA, K
    KISHIMOTO, T
    MIYAMOTO, E
    JOURNAL OF NEUROCHEMISTRY, 1995, 65 : S146 - S146